APA (7th ed.) Citation

Podoll, T., Pearson, P. G., Evarts, J., Ingallinera, T., Bibikova, E., Sun, H., . . . Slatter, J. G. (2019). Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. Drug metabolism and disposition, 47(2), 145-154. https://doi.org/10.1124/dmd.118.084459

Chicago Style (17th ed.) Citation

Podoll, Terry, et al. "Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans." Drug Metabolism and Disposition 47, no. 2 (2019): 145-154. https://doi.org/10.1124/dmd.118.084459.

MLA (9th ed.) Citation

Podoll, Terry, et al. "Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans." Drug Metabolism and Disposition, vol. 47, no. 2, 2019, pp. 145-154, https://doi.org/10.1124/dmd.118.084459.